- Marimastat
-
Marimastat Systematic (IUPAC) name N-[2,2-dimethyl-1- (methylcarbamoyl)propyl]-2- [hydroxy-(hydroxycarbamoyl)methyl]- 4- methyl-pentanamide Clinical data Pregnancy cat. ? Legal status ? Routes oral Identifiers CAS number 154039-60-8 ATC code None PubChem CID 119031 DrugBank APRD00559 ChemSpider 106358 UNII D5EQV23TDS ChEMBL CHEMBL279785 Chemical data Formula C15H29N3O5 Mol. mass 331.408 g/mol (what is this?) (verify) Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1][2]
Marimastat performed poorly in clinical trials,[3] and development was terminated.[citation needed]
References
- ^ "Marimastat". National Cancer Institute. http://www.cancer.gov/drugdictionary/?CdrID=42443.
- ^ Millar, AW; Brown PD, Moore J, et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol 45: 21–6. PMID 9489589.
- ^ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol 22 (23): 4683–90. PMID 15570070.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.